Announcement • Jun 30
Fujian Wanchen Food Group Co., Ltd. to Report First Half, 2026 Results on Aug 29, 2026 Fujian Wanchen Food Group Co., Ltd. announced that they will report first half, 2026 results on Aug 29, 2026 Valuation Update With 7 Day Price Move • May 28
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥180, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 19x in the Food industry in China. Total returns to shareholders of 313% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥319 per share. Price Target Changed • May 03
Price target increased by 7.9% to CN¥282 Up from CN¥262, the current price target is an average from 6 analysts. New target price is 24% above last closing price of CN¥227. Stock is up 38% over the past year. The company is forecast to post earnings per share of CN¥12.66 for next year compared to CN¥7.30 last year. Reported Earnings • Apr 29
First quarter 2026 earnings released: EPS: CN¥3.32 (vs CN¥1.19 in 1Q 2025) First quarter 2026 results: EPS: CN¥3.32 (up from CN¥1.19 in 1Q 2025). Revenue: CN¥16.6b (up 54% from 1Q 2025). Net income: CN¥629.8m (up 193% from 1Q 2025). Profit margin: 3.8% (up from 2.0% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 79% per year, which means it is significantly lagging earnings growth. Announcement • Mar 31
Fujian Wanchen Food Group Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Fujian Wanchen Food Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Reported Earnings • Mar 18
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: CN¥7.30 (up from CN¥1.71 in FY 2024). Revenue: CN¥51.5b (up 59% from FY 2024). Net income: CN¥1.34b (up 358% from FY 2024). Profit margin: 2.6% (up from 0.9% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 6.8%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 88% per year, which means it is significantly lagging earnings growth. Announcement • Mar 17
Fujian Wanchen Food Group Co., Ltd., Annual General Meeting, Apr 07, 2026 Fujian Wanchen Food Group Co., Ltd., Annual General Meeting, Apr 07, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Zhangzhou, Fujian China Price Target Changed • Jan 06
Price target increased by 10% to CN¥224 Up from CN¥203, the current price target is an average from 6 analysts. New target price is 5.5% above last closing price of CN¥213. Stock is up 179% over the past year. The company is forecast to post earnings per share of CN¥5.93 for next year compared to CN¥1.71 last year. Announcement • Dec 31
Fujian Wanchen Biotechnology Group Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 18, 2026 Fujian Wanchen Biotechnology Group Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 18, 2026 Announcement • Dec 05
Zhou Peng completed the acquisition of 5.27% stake in Fujian Wanchen Biotechnology Group Co.,Ltd. (SZSE:300972) from Fujian Mimosa Agricultural Development Co., Ltd., Wang Zening, Zhang Haiguo and Zhangzhou Jinwanchen Investment Co., Ltd. Zhou Peng agreed to acquire 5.27% stake in Fujian Wanchen Biotechnology Group Co.,Ltd. (SZSE:300972) from Fujian Mimosa Agricultural Development Co., Ltd., Wang Zening, Zhang Haiguo and Zhangzhou Jinwanchen Investment Co., Ltd. for CNY 1.3 billion on August 11, 2025. A cash consideration of CNY 1.27 billion valued at CNY 128.3 per share will be paid by the buyer. As part of consideration, CNY 1.27 billion is paid towards common equity of Fujian Wanchen Biotechnology Group Co.,Ltd.
Shen Ying, Guan Yuxia, Li Fan, Liu Dongdong, Li Jianqian of Huaxing Securities Co., Ltd. acted as financial advisor for Fujian Wanchen Biotechnology Group Co.,Ltd. Yao Jia, Zhong Lisha of Grandall Law Firm acted as legal advisor for Fujian Wanchen Biotechnology Group Co.,Ltd. An Suqiang, Yang Yichen of Mazars Certified Public Accountants LLP acted as accountant for Fujian Wanchen Biotechnology Group Co.,Ltd.
Zhou Peng completed the acquisition of 5.27% stake in Fujian Wanchen Biotechnology Group Co.,Ltd. (SZSE:300972) from Fujian Mimosa Agricultural Development Co., Ltd., Wang Zening, Zhang Haiguo and Zhangzhou Jinwanchen Investment Co., Ltd. on December 3, 2024. Announcement • Nov 08
Fujian Wanchen Biotechnology Group Co.,Ltd. Announces Dividend for Third Quarter of 2025 Fujian Wanchen Biotechnology Group Co.,Ltd. announces Cash dividend/10 shares (tax included): CNY 1.50000000 for third quarter of 2025. Major Estimate Revision • Oct 28
Consensus EPS estimates increase by 17%, revenue downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥55.3b to CN¥54.1b. EPS estimate rose from CN¥4.83 to CN¥5.67. Net income forecast to grow 35% next year vs 27% growth forecast for Food industry in China. Consensus price target up from CN¥203 to CN¥216. Share price fell 9.8% to CN¥180 over the past week. Announcement • Oct 23
Fujian Wanchen Biotechnology Group Co.,Ltd. Proposes Cash Dividend for the Third Quarter of 2025 Fujian Wanchen Biotechnology Group Co.,Ltd. at its EGM to be held on November 6, 2025, proposed cash dividend (tax included) of CNY 1.50000000 per share for the third quarter of 2025. New Risk • Oct 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Oct 22
Third quarter 2025 earnings released: EPS: CN¥2.04 (vs CN¥0.47 in 3Q 2024) Third quarter 2025 results: EPS: CN¥2.04 (up from CN¥0.47 in 3Q 2024). Revenue: CN¥14.0b (up 44% from 3Q 2024). Net income: CN¥383.4m (up 361% from 3Q 2024). Profit margin: 2.7% (up from 0.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has increased by 149% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Sep 30
Fujian Wanchen Biotechnology Group Co.,Ltd. to Report Q3, 2025 Results on Oct 22, 2025 Fujian Wanchen Biotechnology Group Co.,Ltd. announced that they will report Q3, 2025 results on Oct 22, 2025 New Risk • Aug 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Aug 28
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥177, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 22x in the Food industry in China. Total returns to shareholders of 1,311% over the past three years. Announcement • Jul 02
Fujian Wanchen Biotechnology Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Fujian Wanchen Biotechnology Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Valuation Update With 7 Day Price Move • Jun 03
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥184, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 21x in the Food industry in China. Total returns to shareholders of 1,284% over the past three years. Announcement • May 13
Fujian Wanchen Biotechnology Group Co., Ltd. Approves Interim Cash Dividend for the Year 2024 Fujian Wanchen Biotechnology Group Co., Ltd. at its AGM held on May 9, 2025 approved interim cash dividend of CNY 4.00 per 10 shares (tax included) for the year 2024. Valuation Update With 7 Day Price Move • May 05
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥165, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 19x in the Food industry in China. Total returns to shareholders of 1,146% over the past three years. Major Estimate Revision • May 01
Consensus EPS estimates increase by 23% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from CN¥3.68 to CN¥4.53. Revenue forecast unchanged at CN¥58.2b. Net income forecast to grow 178% next year vs 27% growth forecast for Food industry in China. Consensus price target up from CN¥124 to CN¥151. Share price rose 19% to CN¥165 over the past week. Reported Earnings • Apr 23
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: CN¥1.71 (up from CN¥0.54 loss in FY 2023). Revenue: CN¥32.3b (up 248% from FY 2023). Net income: CN¥293.5m (up CN¥376.4m from FY 2023). Profit margin: 0.9% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 117% per year, which means it is tracking significantly ahead of earnings growth. Major Estimate Revision • Apr 22
Consensus revenue estimates increase by 15% The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from CN¥50.7b to CN¥58.2b. EPS estimate increased from CN¥3.41 to CN¥3.68 per share. Net income forecast to grow 862% next year vs 24% growth forecast for Food industry in China. Consensus price target up from CN¥98.13 to CN¥124. Share price rose 15% to CN¥130 over the past week. Announcement • Apr 22
Fujian Wanchen Biotechnology Group Co., Ltd. Proposes Final Cash Dividend for 2024 Fujian Wanchen Biotechnology Group Co., Ltd. announced on 21 April 2025 the profit distribution proposal for 2024 as follows: Final cash dividend per 10 shares (tax included) of CNY 4.00000000. Announcement • Apr 20
Fujian Wanchen Biotechnology Group Co., Ltd., Annual General Meeting, May 09, 2025 Fujian Wanchen Biotechnology Group Co., Ltd., Annual General Meeting, May 09, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Zhangzhou, Fujian China New Risk • Apr 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Mar 31
Fujian Wanchen Biotechnology Group Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Fujian Wanchen Biotechnology Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Jan 02
Fujian Wanchen Biotechnology Group Co., Ltd. Approves Cash Dividend for the Third Quarter of 2024 Fujian Wanchen Biotechnology Group Co., Ltd. announced at the EGM held on December 30, 2024, approved Cash dividend/10 shares (tax included) of CNY2.00000000 for the Third Quarter of 2024. Announcement • Dec 31
Fujian Wanchen Biotechnology Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 19, 2025 Fujian Wanchen Biotechnology Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 19, 2025 Major Estimate Revision • Nov 07
Consensus EPS estimates increase by 23% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from CN¥28.4b to CN¥31.0b. EPS estimate increased from CN¥0.925 to CN¥1.14 per share. Net income forecast to grow 651% next year vs 27% growth forecast for Food industry in China. Consensus price target up from CN¥51.73 to CN¥80.63. Share price rose 6.4% to CN¥75.55 over the past week. Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.47 (vs CN¥0.33 loss in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.47 (up from CN¥0.33 loss in 3Q 2023). Revenue: CN¥9.70b (up 261% from 3Q 2023). Net income: CN¥83.1m (up CN¥134.1m from 3Q 2023). Profit margin: 0.9% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has increased by 71% per year, which means it is well ahead of earnings. Announcement • Sep 30
Fujian Wanchen Biotechnology Group Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Fujian Wanchen Biotechnology Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 New Risk • Sep 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). Price Target Changed • Aug 19
Price target increased by 11% to CN¥31.66 Up from CN¥28.54, the current price target is an average from 2 analysts. New target price is 14% above last closing price of CN¥27.74. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥0.90 next year compared to a net loss per share of CN¥0.54 last year. Reported Earnings • Aug 17
Second quarter 2024 earnings released: CN¥0.032 loss per share (vs CN¥0.38 loss in 2Q 2023) Second quarter 2024 results: CN¥0.032 loss per share (improved from CN¥0.38 loss in 2Q 2023). Revenue: CN¥6.08b (up 318% from 2Q 2023). Net loss: CN¥5.30m (loss narrowed 91% from 2Q 2023). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Food industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance. New Risk • Aug 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Buy Or Sell Opportunity • Aug 15
Now 21% overvalued Over the last 90 days, the stock has fallen 18% to CN¥21.55. The fair value is estimated to be CN¥17.82, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 121% over the last 3 years. Meanwhile, the company became loss making. Announcement • Jun 29
Fujian Wanchen Biotechnology Group Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024 Fujian Wanchen Biotechnology Group Co., Ltd. announced that they will report first half, 2024 results on Aug 27, 2024 Board Change • Jun 25
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Non-Independent Director Gai Chun Lin was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Apr 24
Full year 2023 earnings: EPS in line with expectations, revenues disappoint Full year 2023 results: CN¥0.54 loss per share (down from CN¥0.31 profit in FY 2022). Revenue: CN¥9.29b (up CN¥8.74b from FY 2022). Net loss: CN¥82.9m (down 274% from profit in FY 2022). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Food industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Announcement • Apr 23
Fujian Wanchen Biotechnology Group Co., Ltd., Annual General Meeting, May 13, 2024 Fujian Wanchen Biotechnology Group Co., Ltd., Annual General Meeting, May 13, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Zhangzhou, Fujian China Price Target Changed • Apr 17
Price target decreased by 27% to CN¥28.54 Down from CN¥38.97, the current price target is provided by 1 analyst. New target price is 7.9% above last closing price of CN¥26.45. Stock is down 30% over the past year. The company is forecast to post a net loss per share of CN¥0.54 compared to earnings per share of CN¥0.31 last year. Announcement • Mar 30
Fujian Wanchen Biotechnology Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 Fujian Wanchen Biotechnology Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 New Risk • Mar 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Shareholders have been diluted in the past year (12% increase in shares outstanding). Announcement • Dec 30
Fujian Wanchen Biotechnology Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024 Fujian Wanchen Biotechnology Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 23, 2024 New Risk • Oct 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Reported Earnings • Oct 24
Third quarter 2023 earnings released: CN¥0.33 loss per share (vs CN¥0.23 profit in 3Q 2022) Third quarter 2023 results: CN¥0.33 loss per share (down from CN¥0.23 profit in 3Q 2022). Revenue: CN¥2.68b (up CN¥2.53b from 3Q 2022). Net loss: CN¥51.0m (down 243% from profit in 3Q 2022). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Food industry in China. Announcement • Sep 26
Fujian Wanchen Biotechnology Co., Ltd Announces Management Appointments Fujian Wanchen Biotechnology Co. Ltd. announced at the EGM held on September 22, 2023, approved election of Lin Gaichun as non-independent director; Lin Liye and Zhao Jingwen as independent directors and Chen Yiyong and Yao Jianlin as non-employee supervisors. New Risk • Aug 26
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 45% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.9% operating cash flow to total debt). High level of non-cash earnings (45% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Profit margins are more than 30% lower than last year (1.6% net profit margin). New Risk • Aug 19
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 12% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (12% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.6% net profit margin). Reported Earnings • Aug 19
Second quarter 2023 earnings released: CN¥0.38 loss per share (vs CN¥0.15 loss in 2Q 2022) Second quarter 2023 results: CN¥0.38 loss per share (further deteriorated from CN¥0.15 loss in 2Q 2022). Revenue: CN¥1.45b (up CN¥1.37b from 2Q 2022). Net loss: CN¥58.2m (loss widened 158% from 2Q 2022). Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥36.90, the stock trades at a trailing P/E ratio of 74.5x. Average trailing P/E is 39x in the Food industry in China. Total returns to shareholders of 188% over the past year. Announcement • Jul 01
Fujian Wanchen Biotechnology Co., Ltd to Report First Half, 2024 Results on Aug 19, 2023 Fujian Wanchen Biotechnology Co., Ltd announced that they will report first half, 2024 results on Aug 19, 2023 Reported Earnings • Apr 20
First quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.16 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.34 (up from CN¥0.16 in 1Q 2022). Revenue: CN¥761.9m (up CN¥645.2m from 1Q 2022). Net income: CN¥52.6m (up 116% from 1Q 2022). Profit margin: 6.9% (down from 21% in 1Q 2022). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥34.14, the stock trades at a trailing P/E ratio of 63.4x. Average trailing P/E is 40x in the Food industry in China. Total returns to shareholders of 129% over the past year. Valuation Update With 7 Day Price Move • Feb 28
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to CN¥20.12, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 45x in the Food industry in China. Total returns to shareholders of 43% over the past year. Valuation Update With 7 Day Price Move • Feb 13
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥15.08, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 41x in the Food industry in China. Total returns to shareholders of 4.8% over the past year. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.063 loss in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.23 (up from CN¥0.063 loss in 3Q 2021). Revenue: CN¥157.6m (up 91% from 3Q 2021). Net income: CN¥35.8m (up CN¥43.8m from 3Q 2021). Profit margin: 23% (up from net loss in 3Q 2021). Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥12.00, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 39x in the Food industry in China. Total loss to shareholders of 23% over the past year. Reported Earnings • Aug 29
Second quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.18 loss in 2Q 2021) Second quarter 2022 results: CN¥0.15 loss per share (up from CN¥0.18 loss in 2Q 2021). Revenue: CN¥84.9m (up 36% from 2Q 2021). Net loss: CN¥22.5m (loss narrowed 37% from 2Q 2021). Announcement • May 27
Fujian Wanchen Biotechnology Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 06 June 2022 Fujian Wanchen Biotechnology Co. Ltd. announced that 2021 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 2.20000000. Record date: 02 June 2022, Ex-date: 06 June 2022 and Payment date: 06 June 2022. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY0.22000000(10% x CNY 2.20000000) Net cash dividend/10 shares after tax: CNY1.98000000(CNY 2.20000000- CNY 0.22000000). Announcement • May 19
Fujian Wanchen Biotechnology Co., Ltd Announces Dividend for 2021 Fujian Wanchen Biotechnology Co. Ltd. held its Annual General Meeting of 2021 on 16 May 2022 announced cash dividend 10 per shares (tax included): CNY2.20000000 for 2021. Announcement • Apr 27
Fujian Wanchen Biotechnology Co., Ltd Proposes Final Cash Dividend for 2021 Fujian Wanchen Biotechnology Co. Ltd. proposed final cash dividend per 10 shares (tax included) of CNY 2.20000000 for 2021. Reported Earnings • Apr 27
Full year 2021 earnings released: EPS: CN¥0.17 (vs CN¥0.84 in FY 2020) Full year 2021 results: EPS: CN¥0.17 (down from CN¥0.84 in FY 2020). Revenue: CN¥425.5m (down 5.4% from FY 2020). Net income: CN¥24.3m (down 75% from FY 2020). Profit margin: 5.7% (down from 21% in FY 2020). The decrease in margin was primarily driven by higher expenses. Reported Earnings • Oct 27
Third quarter 2021 earnings released: CN¥0.063 loss per share (vs CN¥0.20 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: CN¥82.5m (down 29% from 3Q 2020). Net loss: CN¥8.07m (down 136% from profit in 3Q 2020). Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥16.67, the stock trades at a trailing P/E ratio of 78.4x. Average trailing P/E is 39x in the Food industry in China. Reported Earnings • Aug 30
Second quarter 2021 earnings released: CN¥0.18 loss per share (vs CN¥0.03 loss in 2Q 2020) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: CN¥62.2m (down 23% from 2Q 2020). Net loss: CN¥36.0m (loss widened CN¥32.5m from 2Q 2020). Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥18.16, the stock trades at a trailing P/E ratio of 32x. Average trailing P/E is 34x in the Food industry in China. Reported Earnings • May 01
First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.22 in 1Q 2020) The company reported a poor first quarter result with weaker earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥103.2m (down 4.5% from 1Q 2020). Net income: CN¥23.2m (down 8.6% from 1Q 2020). Profit margin: 23% (in line with 1Q 2020). 
